[go: up one dir, main page]

ATE428423T1 - Aripiprazol-komplex-formulierung und verfahren - Google Patents

Aripiprazol-komplex-formulierung und verfahren

Info

Publication number
ATE428423T1
ATE428423T1 AT03751859T AT03751859T ATE428423T1 AT E428423 T1 ATE428423 T1 AT E428423T1 AT 03751859 T AT03751859 T AT 03751859T AT 03751859 T AT03751859 T AT 03751859T AT E428423 T1 ATE428423 T1 AT E428423T1
Authority
AT
Austria
Prior art keywords
methods
complex formulation
aripiprazole
aripiprazole complex
formulation
Prior art date
Application number
AT03751859T
Other languages
English (en)
Inventor
Manoj Nerurkar
Vijay Naringrekar
Mark Dominick
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE428423(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE428423T1 publication Critical patent/ATE428423T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03751859T 2002-08-20 2003-08-14 Aripiprazol-komplex-formulierung und verfahren ATE428423T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
PCT/US2003/025573 WO2004017897A2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method

Publications (1)

Publication Number Publication Date
ATE428423T1 true ATE428423T1 (de) 2009-05-15

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03751859T ATE428423T1 (de) 2002-08-20 2003-08-14 Aripiprazol-komplex-formulierung und verfahren

Country Status (32)

Country Link
US (8) US7115587B2 (de)
EP (1) EP1542668B1 (de)
JP (1) JP4729306B2 (de)
KR (1) KR101043866B1 (de)
CN (1) CN100335047C (de)
AR (2) AR040887A1 (de)
AT (1) ATE428423T1 (de)
AU (1) AU2003269965B2 (de)
BR (1) BR0313602A (de)
CA (1) CA2495864C (de)
CY (1) CY1110331T1 (de)
DE (1) DE60327225D1 (de)
DK (1) DK1542668T3 (de)
ES (1) ES2322953T3 (de)
GE (1) GEP20063996B (de)
HR (1) HRP20050149B1 (de)
IL (1) IL166623A (de)
IS (1) IS2878B (de)
MX (1) MXPA05001865A (de)
MY (1) MY140793A (de)
NO (1) NO333458B1 (de)
NZ (1) NZ537995A (de)
PE (1) PE20040895A1 (de)
PL (1) PL212428B1 (de)
PT (1) PT1542668E (de)
RS (1) RS51903B (de)
RU (1) RU2342931C2 (de)
SI (1) SI1542668T1 (de)
TW (1) TWI307626B (de)
UA (1) UA79984C2 (de)
WO (1) WO2004017897A2 (de)
ZA (1) ZA200501064B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
WO2004017897A2 (en) 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
TW200529850A (en) * 2003-12-16 2005-09-16 Teva Pharma Methods of preparing aripiprazole crystalline forms
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
GB2442366A (en) * 2005-04-13 2008-04-02 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
KR20080017067A (ko) * 2005-06-03 2008-02-25 엘란 파마 인터내셔널 리미티드 나노입자형 이마티닙 메실레이트 제제
JPWO2006134877A1 (ja) * 2005-06-13 2009-01-08 武田薬品工業株式会社 注射剤
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CA2631233C (en) 2005-11-28 2011-11-08 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
KR101546106B1 (ko) 2007-07-31 2015-08-20 오쓰까 세이야꾸 가부시키가이샤 아리피프라졸 현탁액 및 냉동건조 제형의 제조 방법
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
AU2010266040B2 (en) 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
EP4124616A1 (de) 2009-06-25 2023-02-01 Alkermes Pharma Ireland Limited Heterocyclische verbindungen zur behandlung von neurologischen und psychologischen erkrankungen
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
US8592427B2 (en) 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
EP2897592B1 (de) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
GR1008186B (el) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
HUE057649T2 (hu) 2013-12-24 2022-05-28 Us Gov Veterans Affairs Oxigenált koleszterinszulfátok (OCS) alkalmazása az akut májelégtelenség kezelésére
GR1008442B (el) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN105616344A (zh) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 阿立哌唑注射液及其制备方法
HUE059768T2 (hu) * 2016-08-02 2022-12-28 Univ Virginia Commonwealth 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények
CN119112906A (zh) 2016-08-11 2024-12-13 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
US11033506B2 (en) 2017-11-21 2021-06-15 Sekisui Chemical Co., Ltd. External skin preparation comprising a core-shell structure
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
JP2023551145A (ja) * 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2893175B2 (ja) * 1988-10-31 1999-05-17 大塚製薬株式会社 カルボスチリル誘導体
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
WO2004017897A2 (en) * 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
PL375603A1 (en) 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension

Also Published As

Publication number Publication date
US20090186903A1 (en) 2009-07-23
ZA200501064B (en) 2006-12-27
IS7701A (is) 2005-02-18
HRP20050149A2 (en) 2005-10-31
GEP20063996B (en) 2006-12-11
NZ537995A (en) 2007-11-30
RS20050118A (en) 2007-06-04
CN100335047C (zh) 2007-09-05
PL212428B1 (pl) 2012-09-28
JP4729306B2 (ja) 2011-07-20
NO20050661L (no) 2005-03-16
EP1542668B1 (de) 2009-04-15
MY140793A (en) 2010-01-15
NO333458B1 (no) 2013-06-10
RU2342931C2 (ru) 2009-01-10
US20040077594A1 (en) 2004-04-22
TWI307626B (en) 2009-03-21
TW200405813A (en) 2004-04-16
IL166623A0 (en) 2006-01-15
PL374798A1 (en) 2005-10-31
SI1542668T1 (sl) 2009-08-31
CA2495864A1 (en) 2004-03-04
BR0313602A (pt) 2005-06-21
US20120053145A1 (en) 2012-03-01
US20130045981A1 (en) 2013-02-21
AU2003269965B2 (en) 2008-02-21
US8999952B2 (en) 2015-04-07
US20060234979A1 (en) 2006-10-19
CA2495864C (en) 2011-09-27
US20140235574A1 (en) 2014-08-21
IL166623A (en) 2011-07-31
HRP20050149B1 (hr) 2014-09-12
AR102101A2 (es) 2017-02-01
RS51903B (sr) 2012-02-29
AR040887A1 (es) 2005-04-20
US7115587B2 (en) 2006-10-03
RU2005107471A (ru) 2005-09-10
US20150328335A1 (en) 2015-11-19
EP1542668A4 (de) 2007-10-17
JP2006501240A (ja) 2006-01-12
MXPA05001865A (es) 2005-06-03
CY1110331T1 (el) 2015-01-14
PT1542668E (pt) 2009-06-09
WO2004017897A3 (en) 2004-12-02
UA79984C2 (en) 2007-08-10
DE60327225D1 (de) 2009-05-28
US20110160224A1 (en) 2011-06-30
US7550445B2 (en) 2009-06-23
KR101043866B1 (ko) 2011-06-22
CN1674882A (zh) 2005-09-28
WO2004017897A2 (en) 2004-03-04
DK1542668T3 (da) 2009-07-20
AU2003269965A1 (en) 2004-03-11
ES2322953T3 (es) 2009-07-02
PE20040895A1 (es) 2004-11-20
IS2878B (is) 2014-04-15
EP1542668A2 (de) 2005-06-22
KR20050040927A (ko) 2005-05-03

Similar Documents

Publication Publication Date Title
ATE428423T1 (de) Aripiprazol-komplex-formulierung und verfahren
DE602005015421D1 (de) Direktkomprimierte formulierung und verfahren
DE602004006981D1 (de) Datenabrufende und -übertragende vorrichtungen und verfahren
DE602004017342D1 (de) Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP1504429A4 (de) Verfolgungssystem und zugeordnetes verfahren
CY2014033I2 (el) Παραγωγα κινολινης και η χρηση τους ως μυκοβακτηριακων αναστολεων
DE602004015326D1 (de) Schutz-bus-schnittstelle und verfahren
DE602004018986D1 (de) Vorrichtungen, verfahren und computerprogrammproduisationsfunktionen
DE602004022347D1 (de) Testeinrichtung und Testverfahren
EP1635515A4 (de) Mobilengerät und zugehöriges weiterreich verfahren
DE60307766D1 (de) Gewürzmittel und Verfahren zu seiner Herstellung
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DE60208700D1 (de) Schälgerät und zugehörige verfahren
DE60330080D1 (de) Pin Halterung und Verfahren
DE60309411D1 (de) Pollensensor und Verfahren
DE60333155D1 (de) Simultandolmetschen- System und Verfahren
DE60336039D1 (de) Verstellbares Bohrgerät und assoziiertes Verfahren
DE60320625D1 (de) Röntgenvorrichtung und Verfahren
EP1455841A4 (de) Osteopontin-verwandte zusammensetzungen und verfahren
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
DE602004027703D1 (de) Schwefelfreie zusammensetzung und schmiermittelzusammensetzung und verfahren davon
DE60317443D1 (de) H-Brückenvorrichtung und Verfahren
ATE459726T1 (de) Verfahren und produkte
DE60327836D1 (de) PVD-Vorrichtung und Verfahren
ATE418339T1 (de) Zusammensetzung und verfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1542668

Country of ref document: EP